The New Freedom Commission on Mental Health was established by
U.S. President George W. Bush in April 2002 to conduct a comprehensive study of
the U.S. mental health service delivery system and make recommendations about
pharmaceutical treatment. The commission, using the Texas Medication
Algorithm Project (TMAP) as a blueprint, subsequently recommended screening of
American adults for possible mental illnesses, and children for emotional
disturbances in order to increase the use of highly controversial and
inadequately tested pharmaceutical drugs. Many of these drugs were found
to be dangerous and had serious long term health effects as well as being so
physically addictive that it was almost impossible to take the patient off them
after they had been initiated. There are few potential benefits from the Texas
Medical Algorithm plan, except increased profits for pharmaceutical
companies. There are serious concerns about the potential for
unnecessarily causing neurological damage and contributing to increased medical
costs, potential substance abuse and pharmaceutical drug dependence.
NAMI and other pharmaceutical industry front organizations are
used to compromise of scientific integrity under color of authority.
Organizations that protect the civil rights of the disabled look askance
at the irony of the use of the word freedom, contending the commission is yet
another example of the excesses of drug industry marketing. The effects
of the New Freedom Commission on Mental Health recommendations are to simply
foster drug use rather than the prevention of mental illness and use of
alternative treatment modalities.
TMAP, which was created in 1995 while President Bush was
governor of Texas, began as an alliance of individuals from the University of
Texas, the pharmaceutical industry, and the mental health and corrections
systems of Texas. Through the guise of TMAP, critics contend, the drug industry
has methodically influenced the decision making of elected and appointed public
officials to gain access to citizens in prisons and State psychiatric
hospitals.
Allen Jones was the investigator for the Office of Inspector
General regarding the approval of psychotropic drugs by the Food and Drug
Administration. Allen Jones, was a former investigator in the Commonwealth of
Pennsylvania Office of Inspector General (OIG), Bureau of Special
Investigations. His very detailed report can be found on the
Psychrights.org website.
Many critics contend that the strategy behind the commission was
developed by the pharmaceutical industry, advancing the theory that the primary
purpose of the commission was to recommend implementation of TMAP based
algorithms on a nationwide basis. TMAP, which advises the use of newer, more
expensive medications, has itself has been the subject of controversy in Texas,
Pennsylvania and other states where efforts have been made to implement its
use.
Jones wrote a lengthy report in which he stated that, behind the
recommendations of the New Freedom Commission, was the
"political/pharmaceutical alliance." It was this alliance, according
to Jones, which developed the Texas project, specifically to promote the use of
newer, more expensive antipsychotics and antidepressants. He further claimed
this alliance was "poised to consolidate the TMAP effort into a
comprehensive national policy to treat mental illness with expensive, patented
medications of questionable benefit and deadly side effects, and to force
private insurers to pick up more of the tab."
A coalition of over 100 advocacy organizations, united under the
banner of Mindfreedom.org in representing the psychiatric survivors movement,
has been galvanized by their strong opposition to the New Freedom Commission.
See also articles on this website
http://psychrights.org/articles/articles.htm
Opponents of the New Freedom Commission plan have questioned the
motives of the commission, largely from a civil liberties perspective,
asserting the initiative campaign is little more than a thinly veiled proxy for
the pharmaceutical industry, which, in its pursuit of profits, is too eager to
foster psychotropic medication interventions. Some opponents contend that its
objectives are to foster chemical behavior control of American citizens.
The Food and Drug Administration (FDA) was receiving reports of increased rates
of suicide, especially during the first months of drug use and widespread extra
label use of these medications in direct violation of their black box warning
about potential adverse side effects.
"TeenScreen" which was a program to screen every
American shoolchild for mental disease, represented naked pharmaceutical
company greed. Even before these New Freedom Commission recommendations
were made there were 15 million Americans on Zyprexa (7.4 million) and
Risperdal (7.6 million) alone in 2002. Sales of atypical
antipsychotic drugs reached $6.4 billion, making them the fourth best selling
class of drugs in America. The combined sales of antidepressants and antipsychotics
jumped from around $500 million in 1986 to nearly $20 billion in 2004 – a
40-fold increase. (Anatomy of an Epidemic: Psychiatric Drugs and the
Astonishing Rise of Mental Illness in America by Robert Whitaker, Ethical Human
Psychology and Psychiatry, Volume 7, Number I , Spring 2005) The article
is available at:http://psychrights.org/Articles/EHPPPsychDrugEpidemic(Whitaker).pdf
In April, 2000, AHRP filed a complaint about the experiment,
with the Office of Human Research Protection--see:http://www.ahrp.org/Initiatives/YaleComplaint.php
But this was not enough profit for the pharmaceutical companies
and therefore additional marketing and political pressure were used to create a
public mental health policy to screen children and get more of them on atypical
antipsychotics. This was the TeenScreen program which was designed
to diagnose mental illness in teenagers, but has been shown to be coercive and
unreliable. The same political/pharmaceutical alliance that
generated the Texas project is behind the New Freedom Commission.
Using the marketing strategy behind TeenScreen, this alliance is lobbying to
consolidate the TMAP effort into a comprehensive national policy and thus force
on children and adults expensive, patented medications of questionable
benefit and deadly side effects. The
global pharmaceutical market is forecast to grow to US $842 billion in 2010
(Pharmaceutical Market Trends 2006-2010 by S. Seget)